Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and nerve impulse transmission; dextrose is a carbohydrate source for energy metabolism; sodium chloride provides sodium and chloride ions for extracellular fluid balance and osmotic pressure.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous replacement of potassium in patients with hypokalemia,Maintenance of fluid and electrolyte balance,Provision of caloric (dextrose) in patients requiring IV fluids
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion, 1000 m L to 2000 m L per 24 hours, adjusted based on serum potassium, glucose, and sodium levels.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Potassium: not applicable (regulated by homeostasis); dextrose: <30 minutes; sodium: not applicable.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized via glycolysis and the citric acid cycle; sodium and chloride are excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Potassium: renal (90%), fecal (10%); dextrose: metabolized to CO2 and water; sodium: renal (95%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Potassium: negligible (<5%); dextrose: none; sodium: none.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Potassium: approximately 0.5 L/kg (total body water); dextrose: distributed to total body water; sodium: mainly extracellular fluid (0.2 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 30-60 m L/min: reduce potassium dose by 50% or monitor serum potassium frequently; GFR <30 m L/min: contraindicated unless serum potassium is low and monitored closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific Child-Pugh based adjustment for potassium; dextrose may require monitoring in severe hepatic impairment due to insulin resistance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based: 2-4 m Eq/kg/day potassium, with dextrose 5-10 mg/kg/min and sodium 2-4 m Eq/kg/day, titrated to serum electrolytes.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: start at low end of adult range, monitor renal function and serum electrolytes frequently due to age-related decline in renal function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Potassium chloride injection concentrate must be diluted before use; rapid infusion or undiluted administration can cause fatal hyperkalemia and cardiac arrest.
None.
Monitor serum potassium, glucose, and electrolytes frequently during infusion,Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia,Do not administer undiluted or via rapid intravenous infusion,Risk of hyperkalemia, especially with impaired renal function,Risk of fluid overload in patients with heart failure or edema,Risk of hyperglycemia from dextrose content
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Severe renal failure with oliguria or anuria,Untreated Addison's disease,Hyperchloremia,Patients with known hypersensitivity to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, patients should be aware that dietary intake of potassium (e.g., bananas, oranges, potatoes, leafy greens) and sodium (e.g., table salt, processed foods) may affect electrolyte balance. Those with renal impairment or on potassium-sparing diuretics should avoid excessive potassium-rich foods. Dextrose content may affect blood glucose; diabetic patients should monitor carbohydrate intake.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride are normal physiologic constituents. No teratogenic risk is attributed at therapeutic doses. IV administration during pregnancy is indicated for fluid and electrolyte replacement as needed. No trimester-specific risks identified.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, dextrose, and sodium chloride are endogenous substances normally present in breast milk. IV administration does not significantly alter milk composition. M/P ratio not applicable as these are normal blood constituents. Compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment required for pregnancy. However, pregnancy increases plasma volume and glomerular filtration rate, potentially altering electrolyte and fluid requirements. Individualize dose based on serum electrolyte monitoring and clinical status.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This solution provides 0.22% potassium chloride (approximately 2 m Eq K+ per 100 m L), which is a maintenance potassium concentration commonly used to prevent hypokalemia in patients with normal renal function. Monitor serum potassium and renal function closely, especially in patients with impaired renal function, those on potassium-sparing diuretics, or with cardiac conditions. Rate of infusion should be guided by serum potassium levels and clinical status; rapid infusion may cause hyperkalemia and cardiac arrhythmias. Use with caution in patients with severe renal impairment (oliguria, anuria) or conditions predisposing to hyperkalemia. Also note the dextrose content (5%) may cause hyperglycemia in diabetic patients; adjust insulin accordingly. The sodium chloride content (0.9%) provides isotonicity and sodium replacement; be cautious in patients with hypertension, heart failure, or edema.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This intravenous fluid contains potassium, dextrose (sugar), and salt to help maintain your body's electrolyte and fluid balance.,Inform your healthcare provider if you have kidney problems, heart disease, diabetes, or are taking any medications, especially diuretics (water pills) or ACE inhibitors.,Tell your nurse or doctor immediately if you experience chest pain, irregular heartbeat, muscle weakness, tingling, or difficulty breathing during the infusion.,Do not adjust the infusion rate; it will be controlled by your healthcare team to ensure safety.,If you have diabetes, your blood sugar will be monitored closely as the dextrose content may affect your glucose levels.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and nerve impulse transmission; dextrose is a carbohydrate source for energy metabolism; sodium chloride provides sodium and chloride ions for extracellular fluid balance and osmotic pressure.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion, 1000 m L to 2000 m L per 24 hours, adjusted based on serum potassium, glucose, and sodium levels.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are normal physiologic constituents. No teratogenic risk is attributed at therapeutic doses. IV administration during pregnancy is. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.